Stocklytics Platform
Asset logo for symbol AXSM
Axsome Therapeutics
AXSM63
$98.42arrow_drop_down1.70%-$1.70
High Growth
Asset logo for symbol AXSM
AXSM63

$98.42

arrow_drop_down1.70%
Key Stats
Open$100.21
Prev. Close$100.10
EPS-6.58
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range97.68
102.08
52 Week Range55.02
107.09
Ratios
EPS-6.58
Fundamentals
Payout Ratio-
Industry average yield2.72%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

AXSM-
US Healthcare Sector-
US Market-
warning

AXSM / Market

AXSM lose to the US Market which returned -0.66% over the last twenty four hours.
warning

AXSM / Healthcare Sector

AXSM lose to the US Healthcare sector which returned 2.91% over the last twenty four hours.

Axsome Therapeutics (AXSM) Statistics

Axsome Therapeutics Inc (AXSM) is a biopharmaceutical company that focuses on developing novel therapies for central nervous system (CNS) disorders. The company is committed to transforming the lives of patients suffering from debilitating neurological conditions through its innovative drug development programs. With a dedicated team of scientists and researchers, Axsome Therapeutics is at the forefront of revolutionizing CNS therapeutics.
When it comes to statistics, Axsome Therapeutics Inc (AXSM) stands out among its peers. The stock has shown impressive performance in recent years, consistently outperforming the sector. Investors can rely on AXSM to provide strong returns on their investment.
add Axsome Therapeutics  to watchlist

Keep an eye on Axsome Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How much debt does Axsome Therapeutics (AXSM) have?

Axsome Therapeutics (AXSM) has a total debt of $192.3M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$135.04M.
help

What is the EPS of Axsome Therapeutics (AXSM) stock?

The Earnings Per Share (EPS) for Axsome Therapeutics (AXSM), calculated on a diluted basis, is -$6.58. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the PE ratio of Axsome Therapeutics (AXSM) stock?

The PE ratio for Axsome Therapeutics (AXSM) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

How has Axsome Therapeutics (AXSM) stock's performance compared to its sector and the market over the past year?

Over the past year, Axsome Therapeutics (AXSM) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 30.75%, Axsome Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 60.37%, it has fallen short of the market average. This comparison highlights Axsome Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the operating margin of Axsome Therapeutics (AXSM) stock?

The operating margin for Axsome Therapeutics (AXSM) is -44.13%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Axsome Therapeutics (AXSM) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Axsome Therapeutics (AXSM) is -$244.62M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

Take Your Investments to a Whole New Level